文献速递胸部肿瘤

BELIEF试验中循环游离DNA EGFR突变演变及临床影响

Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial.
PubMed 文献 · J Thorac Oncol · 2019-12-05

BELIEF试验预设二次分析,前瞻性收集晚期EGFR阳性NSCLC患者血样,用实时定量PCR检测cfDNA EGFR突变。基线血EGFR exon19/21突变阳性率为60.4%,与更短PFS相关;进展时阳性率50.0%,与更短OS相关。

要点

  • 基线血EGFR exon19/21阳性者PFS 11.4个月,阴性者22.9个月,差异显著。
  • 进展时血EGFR exon19/21阳性者中位OS 21.7个月,阴性者37.4个月。
  • 基线血突变阴性者进展后93%仍为阴性,p.T790M仅2例可检出。

核心结论

  • 纵向血检EGFR突变可提供有价值的临床信息。
  • 基线cfDNA EGFR突变阳性与更短PFS相关,进展时阳性与更短OS相关。
  • 基线血突变阴性者复发时几乎均为阴性。

研究设计与样本

  • BELIEF试验预设二次分析,厄洛替尼联合贝伐珠单抗治疗晚期EGFR阳性NSCLC。
  • 前瞻性收集基线、疗效评估和进展时血样,送中心实验室。
  • 纯化cfDNA,用经验证的实时定量PCR检测EGFR突变。

主要发现

  • 91份基线血样中55份(60.4%)检出EGFR exon19/21突变。
  • 基线阳性者PFS 11.4个月(95%CI 9.0-14.8),阴性者22.9个月(95%CI 9.5-33.9),log-rank p=0.0020。
  • 74份疗效评估血样中仅3份(4.1%)检出exon19/21突变。
  • 58例进展时血样中29例(50.0%)exon19/21阳性,中位OS 21.7个月(95%CI 17.0-30.9)vs 阴性者37.4个月(95%CI 22.6-53.1),log-rank p=0.011。
  • 48例三时间点血样可用者中,14例基线exon19/21阴性者进展后13例(93%)持续阴性,p.T790M仅2例血中检出。

临床怎么用

  • 可考虑纵向监测血cfDNA EGFR突变辅助预后评估。
  • 基线血EGFR突变阳性提示PFS可能较短。
  • 进展时血EGFR突变阳性提示OS可能较短。

局限性

  • 为BELIEF试验二次分析,样本量有限。
  • 检测方法为实时定量PCR,未涵盖全部突变类型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Longitudinal evaluation of mutations in blood samples was a prespecified secondary objective in the BELIEF trial of erlotinib and bevacizumab in advanced EGFR-positive NSCLC. Here, we report the testing results and explore the correlation of EGFR status in blood with clinical outcomes. METHODS: Blood samples were prospectively collected from patients at baseline, at response evaluation, and at progression and sent to a central laboratory. Circulating free DNA was purified and EGFR mutations were analyzed with a validated real-time quantitative polymerase chain reaction assay. RESULTS: EGFR exon 19/21 mutations were detected in 55 of 91 baseline blood samples (60.4%) and correlated with a significantly worse progression-free survival: 11.4 months (95% confidence interval [CI]: 9.0-14.8 mo) for the patients who were positive versus 22.9 months (95% CI: 9.5-33.9 mo) for those who were negative (log-rank p = 0.0020). Among the 74 samples at response, exon 19/21 mutations were detected only in three samples (4.1%). In contrast, 29 of 58 patients (50.0%) were exon 19/21 positive at progression and showed a significantly worse median overall survival of 21.7 months (95% CI: 17.0-30.9 mo) compared with 37.4 months (95% CI: 22.6-53.1 mo) for those who were negative (log-rank p = 0.011). Blood samples at the three time points were available for 48 patients. Of those, among 14 exon 19/21 EGFR-negative at presentation, 13 (93%) were persistently negative for the sensitizing mutations after progression and the p.T790M could only be detected in the blood of two patients. CONCLUSIONS: Longitudinal testing of EGFR mutations in blood can offer valuable clinical information. In patients of the BELIEF study, detection of EGFR mutations in circulating free DNA at presentation was associated with shorter progression-free survival, whereas positivity at progression correlated with shorter overall survival. Finally, patients negative in blood at presentation were almost invariably negative at relapse.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Molina-Vila MA, Stahel RA, Dafni U, et al. Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial. J Thorac Oncol. 2019. PMID: 31812754. doi:10.1016/j.jtho.2019.11.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。